| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2003.02.083 |
| P698 | PubMed publication ID | 12525533 |
| P2093 | author name string | Glenn J Bubley | |
| Steven P Balk | |||
| Yoo-Joung Ko | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 383-391 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Biology of prostate-specific antigen. | |
| P478 | volume | 21 |
| Q42026389 | "True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer |
| Q36084063 | A Review on the Clinical Utility of PSA in Cancer Prostate |
| Q38299437 | A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth |
| Q41713609 | A hospital based study on reference range of serum prostate specific antigen levels. |
| Q47950750 | A proof of principal study on the use of direct PCR of semen and spermatozoa and development of a differential isolation protocol for use in cases of alleged sexual assault |
| Q38353715 | A role of aryl hydrocarbon receptor in the antiandrogenic effects of polycyclic aromatic hydrocarbons in LNCaP human prostate carcinoma cells |
| Q38074010 | Aberrant PSA glycosylation--a sweet predictor of prostate cancer. |
| Q42615371 | Aberrant sialylation of a prostate-specific antigen: Electrochemical label-free glycoprofiling in prostate cancer serum samples |
| Q39748389 | Action mechanism and signal pathways of Psidium guajava L. aqueous extract in killing prostate cancer LNCaP cells |
| Q28829239 | Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy |
| Q39961330 | An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines |
| Q37691113 | An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis |
| Q35147686 | Analysis of prostate-specific antigen transcripts in chimpanzees, cynomolgus monkeys, baboons, and African green monkeys. |
| Q57107694 | Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations |
| Q39293549 | Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. |
| Q37134480 | Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells |
| Q57816352 | Association between PSA and age in Macuxi ethnic population of the Brazilian Amazon forest region |
| Q33584215 | Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma |
| Q34544617 | BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer |
| Q89697292 | Beyond PSA: The Role of Prostate Health Index (phi) |
| Q38420320 | Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. |
| Q37238101 | Beyond PSA: the next generation of prostate cancer biomarkers |
| Q90335873 | Bioconjugated, Single-Use Biosensor for the Detection of Biomarkers of Prostate Cancer |
| Q36682278 | Bone and prostate cancer cell interactions in metastatic prostate cancer |
| Q38852467 | Can glycoprofiling be helpful in detecting prostate cancer? |
| Q36909145 | Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? |
| Q101226605 | Characterisation of the main PSA glycoforms in aggressive prostate cancer |
| Q64230293 | Characterization of Monoclonal and Polyclonal Antibodies Recognizing Prostate Specific Antigen: Implication for Design of a Sandwich ELISA |
| Q39819484 | Characterization of de novo synthesized proteins released from human colorectal tumour explants |
| Q33919829 | Chitotriosidase, a marker of innate immunity, is elevated in patients with primary breast cancer |
| Q37705997 | Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase |
| Q35650689 | Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer |
| Q35762682 | Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer |
| Q54301350 | Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. |
| Q40002575 | Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study |
| Q54191300 | Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients. |
| Q37589249 | Clinicopathological study of 9 cases of prostate cancer involving the rectal wall |
| Q41839859 | Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies |
| Q34497704 | Comprehensive review of the anatomy and physiology of male ejaculation: Premature ejaculation is not a disease |
| Q45943371 | Computer-aided biomarker discovery for precision medicine: data resources, models and applications. |
| Q38835384 | Cysteine-rich secretory protein 3 plays a role in prostate cancer cell invasion and affects expression of PSA and ANXA1. |
| Q38955984 | DNA fragmentation, caspase 3 and prostate-specific antigen genes expression induced by arsenic, cadmium, and chromium on nontumorigenic human prostate cells |
| Q38544772 | DNA vaccination for prostate cancer: key concepts and considerations |
| Q34284652 | Dendritic cell-based immunotherapy for prostate cancer |
| Q33234340 | Detection and quantification of protein biomarkers from fewer than 10 cells |
| Q57818448 | Detection, quantification, and profiling of PSA: current microarray technologies and future directions |
| Q51046944 | Determining the binding affinities of prostate-specific antigen to lectins: SPR and microarray approaches. |
| Q91953116 | Development and Evaluation of an Immunoglobulin Y-Based ELISA for Measuring Prostate Specific Antigen in Human Serum |
| Q53259763 | Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. |
| Q27331332 | Differential effects of tissue culture coating substrates on prostate cancer cell adherence, morphology and behavior |
| Q42632618 | Does prostate specific antigen density correlates with aggressiveness of the prostate cancer? |
| Q33246793 | Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line |
| Q83974003 | Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population |
| Q35069651 | Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial |
| Q38101491 | Electrical biosensors and the label free detection of protein disease biomarkers |
| Q35027986 | Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles. |
| Q34086670 | Enzyme-triggered gelation: targeting proteases with internal cleavage sites |
| Q45095952 | Estrogen enhancement of androgen-responsive gene expression in hormone-induced hyperplasia in the ventral prostate of F344 rats |
| Q50900158 | Evaluation of a CLEIA automated assay system for the detection of a panel of tumor markers. |
| Q49967423 | Extraction, purification of prostate-specific antigen (PSA), and establishment of radioimmunoassay system as a diagnostic tool for prostate disorders. |
| Q37725559 | FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription |
| Q37970472 | Female postmating immune responses, immune system evolution and immunogenic males |
| Q38484434 | Functional analysis of human cancer-associated genes and their association with the testes and epididymis |
| Q35356872 | Functional biomarkers of depression: diagnosis, treatment, and pathophysiology |
| Q42559393 | Glycoproteomics: identifying the glycosylation of prostate specific antigen at normal and high isoelectric points by LC-MS/MS. |
| Q37215561 | Haptoglobin is a serological biomarker for adenocarcinoma lung cancer by using the ProteomeLab PF2D combined with mass spectrometry |
| Q33935044 | High-resolution functional proteomics by active-site peptide profiling |
| Q41704496 | Horizontally Aligned Carbon Nanotube Based Biosensors for Protein Detection. |
| Q55071360 | Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer. |
| Q28184208 | Human and mouse proteases: a comparative genomic approach |
| Q28259758 | Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin |
| Q33812900 | Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes |
| Q34417941 | Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit |
| Q34810177 | Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring |
| Q40217830 | Identification of putative androgen receptor interaction protein modules: cytoskeleton and endosomes modulate androgen receptor signaling in prostate cancer cells |
| Q88047671 | Identification of spermatozoa by tissue-specific differential DNA methylation using bisulfite modification and pyrosequencing |
| Q26767044 | Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer |
| Q37061769 | Immunotherapy and immune evasion in prostate cancer |
| Q38212231 | Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. |
| Q92028104 | Increased Soluble CrkL in Serum of Breast Cancer Patients Is Associated with Advanced Disease |
| Q33507490 | Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. |
| Q38383521 | Inflammation and prostate cancer: friends or foe? |
| Q34189747 | Inverse relationship between PSA and IL-8 in prostate cancer: an insight into a NF-κB-mediated mechanism |
| Q37628655 | Invited Review Article: Review of centrifugal microfluidic and bio-optical disks |
| Q39439477 | Involvement of interleukin-1β mediated nuclear factor κB signalling pathways to down-regulate prostate-specific antigen and cell proliferation in LNCaP prostate cancer cells |
| Q26862434 | Kallikreins as biomarkers for prostate cancer |
| Q37985937 | Label-free electrical detection using carbon nanotube-based biosensors |
| Q63966245 | Les formes moléculaires du PSA |
| Q39852952 | Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers |
| Q24312968 | Major role of human KLK14 in seminal clot liquefaction |
| Q30954345 | Mass spectrometry-based clinical proteomics |
| Q34794028 | Metabolic imbalance and prostate cancer progression. |
| Q81379607 | Metastatic prostate cancer with a normal prostate-specific antigen level |
| Q26823077 | Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies |
| Q34464315 | Microfluidic Western blotting of low-molecular-mass proteins |
| Q50133991 | Molecular Biomarkers in the Clinical Management of Prostate Cancer. |
| Q26772870 | Molecular Imaging of Biomarkers in Breast Cancer |
| Q40441090 | Molecular aspects of prostate cancer: implications for future directions |
| Q40083765 | Multi-factors including Inflammatory/Immune, Hormones, Tumor-related Proteins and Nutrition associated with Chronic Prostatitis NIH IIIa+b and IV based on FAMHES project |
| Q64122986 | Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers |
| Q47433004 | NAD(P)H-quinone oxidoreductase 1 silencing aggravates hormone-induced prostatic hyperplasia in mice. |
| Q38220183 | New concepts concerning prostate cancer screening. |
| Q24619151 | New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer |
| Q26771927 | Nothing Boring About Boron |
| Q33282603 | Nuclear structure as a source of cancer specific biomarkers |
| Q28242416 | Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents |
| Q42055856 | Overexpression of cofilin 1 in prostate cancer and the corresponding clinical implications |
| Q39783600 | Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis |
| Q39644611 | Overexpression of ribosomal L1 domain containing 1 is associated with an aggressive phenotype and a poor prognosis in patients with prostate cancer. |
| Q40262739 | Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells |
| Q52727709 | PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis. |
| Q35609528 | PSA markers in prostate cancer detection |
| Q38502644 | Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy |
| Q21145283 | Pervasive adaptive evolution in primate seminal proteins |
| Q79075846 | Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression |
| Q27324520 | Plasma carotenoids and tocopherols in relation to prostate-specific antigen (PSA) levels among men with biochemical recurrence of prostate cancer |
| Q87378380 | Plasma human neutrophil proteins-1, -2, and -3 levels in patients with bladder cancer |
| Q54419688 | Polymorphisms in the AR and PSA genes as markers of susceptibility and aggressiveness in prostate cancer. |
| Q41466522 | Population-based Prostate Cancer Screening in Kazakhstan |
| Q36670466 | Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. |
| Q35235153 | Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006 |
| Q37252155 | Prospective evaluation of operating characteristics of prostate cancer detection biomarkers |
| Q27013843 | Prostate cancer relevant antigens and enzymes for targeted drug delivery |
| Q40425949 | Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft. |
| Q92636843 | Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy |
| Q36748783 | Proteomic analysis of colorectal cancer: prefractionation strategies using two-dimensional free-flow electrophoresis |
| Q38132914 | Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for protein markers with potential clinical utility |
| Q55412648 | Quantitative evolutionary proteomics of seminal fluid from primates with different mating systems. |
| Q40296201 | Reference Ranges of Age-Related Prostate-Specific Antigen in Men without Cancer from Beijing Area |
| Q40592803 | Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells |
| Q35897569 | Research Resource: Androgen Receptor Activity Is Regulated Through the Mobilization of Cell Surface Receptor Networks |
| Q54589955 | STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. |
| Q39001150 | Schlafen 12 expression modulates prostate cancer cell differentiation |
| Q37801615 | Screening, risk assessment, and the approach to therapy in patients with prostate cancer |
| Q46109803 | Secreted gelsolin desensitizes and induces apoptosis of infiltrated lymphocytes in prostate cancer |
| Q41340371 | Serum prostate-specific antigen levels in men with prediabetes: a cross-sectional study |
| Q42945647 | Serum prostate‐specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu |
| Q33637037 | Shikonin inhibits the growth of human prostate cancer cells via modulation of the androgen receptor |
| Q34276511 | Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker |
| Q37058937 | Spongian diterpenoids inhibit androgen receptor activity |
| Q36922015 | Systematic, evidence-based discovery of biomarkers at the NCI. |
| Q57105900 | Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer |
| Q38295983 | Targeted prodrug approaches for hormone refractory prostate cancer. |
| Q38739244 | Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation |
| Q36575243 | Targeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer. |
| Q60950097 | The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients |
| Q33688960 | The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling. |
| Q80297374 | The effective management of biochemical recurrence in patients with prostate cancer |
| Q34699785 | The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis |
| Q37606806 | The influence of PSA-RNA yield on the analysis of expressed prostatic secretions (EPS) for prostate cancer diagnosis |
| Q46315125 | The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels |
| Q34403242 | The search for secreted proteins in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of NBL1 is highly restricted to the prostate and is related to cancer progression |
| Q35861497 | The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers |
| Q26750620 | Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer |
| Q52688486 | Thyroid and reproductive hormones disruption as well as kallikrein-3 level in dimethyl nitrosamine-induced toxicity: Effects of ascorbate treatment in male wistar rats. |
| Q36778322 | Towards Understanding Male Infertility After Spinal Cord Injury Using Quantitative Proteomics |
| Q28545213 | Towards engineering hormone-binding globulins as drug delivery agents |
| Q41977894 | Tumor-associated antigens for specific immunotherapy of prostate cancer |
| Q28248233 | UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells |
| Q37404644 | Ultrasensitive Luminescent In Vitro Detection for Tumor Markers Based on Inorganic Lanthanide Nano-Bioprobes. |
| Q50216092 | Urease immobilized fluorescent gold nanoparticles for urea sensing. |
| Q58562073 | Urinary markers aiding in the detection and risk stratification of prostate cancer |
| Q55508834 | V-ATPase-dependent repression of androgen receptor in prostate cancer cells. |
| Q38626590 | Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience |
| Q38957297 | Walnut polyphenol metabolites, urolithins A and B, inhibit the expression of the prostate-specific antigen and the androgen receptor in prostate cancer cells |
| Q34196086 | miR 488* inhibits androgen receptor expression in prostate carcinoma cells |
| Q38087057 | miRNA profiling of cancer |
Search more.